Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) versus H-CYTE (OTCMKTS:HCYTD) Critical Review

Earnings and Valuation

This table compares Defiance Daily Target 2X Long LMND ETF and H-CYTE”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF	$437.66 million	0.01	$15.17 million	$0.51	32.53
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than H-CYTE.

Risk and Volatility

Defiance Daily Target 2X Long LMND ETF has a beta of 9.29, indicating that its stock price is 829% more volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Institutional and Insider Ownership

87.8% of Defiance Daily Target 2X Long LMND ETF shares are held by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are held by insiders. Comparatively, 5.2% of H-CYTE shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Defiance Daily Target 2X Long LMND ETF and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%
H-CYTE	-450.40%	N/A	-777.68%

Summary

Defiance Daily Target 2X Long LMND ETF beats H-CYTE on 8 of the 9 factors compared between the two stocks.

About Defiance Daily Target 2X Long LMND ETF

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.